Association of Plasma Interlukin-6 in Metastatic & Non-Metastatic Prostate Cancer Patients presented to a Tertiary Care Hospital in Lahore Pakistan.

Munazza Khan, Zaffar uddin, Zarghuna Khan, Yasir Khan, Zarsanga Haider, Sahibzada Saeed Jan


Background: Prostate cancer (PC) is a complex, multi-factorial disease. In spite of its high prevalence, the Pathophysiology of the
PC progression is poorly understood. Cytokines play important role in immune regulation. Cytokines (IL-6) regulates growth of
many tumor cells including prostate cancer, therefor it can be used as a marker for PC.
Objectives: To measure and compare the levels of IL-6 between metastatic and non- metastatic prostate cancer patients.
Material and Methods: This study was a Cross-sectional analytical and was conducted in the Department of physiology Federal
Psotgraduate Medical Institute (FPGMI) Lahore with collaboration of Urology department of Sheikh Zayed hospital Lahore.
Patients with prostate cancer registered with Urology department, Sheikh Zayed Hospital Lahore were recruited for the study.
Patients with inflammatory conditions, auto-immune diseases, obesity and Alzimer's disease were excluded. A standard Elisa kit
(Thermo scientific made in USA) was used for estimation of serum IL-6 levels. Data was recorded on a structured checklist, which
contained basic demographic data along with finding of prostate specific antigen (PSA), prostatic biopsy, bone scan and serum IL-6
levels. Data was analyzed through SPSS version 20 for descriptive statistics.
Results: A total of 50 (25 metastatic and 25 non-metastatic) prostate cancer patients were being part of the present study. The
mean PSA level was 364.42 ± 86.7 among metastatic prostate cancer patients as compared to 30.71 ±23.48 non- metastatic,
indicating significant difference (p =0.001). Similarly mean Gleason score was high (7.16±0.85) among metastatic prostate cancer
patients as compared to 6.28±0.54 among non-metastatic one. Significant difference (p=0.014) was observed regarding IL-6. It
was 25.73±80.48 among metastatic patients in comparison with 1.56±1.38 among non-metastatic patients. There was strong
correlation between PSA and Gleason score (r= 0.479**, p<0.001). Also positive association was found between IL-6 and PSA, (r=
0.285*, p=0.045).
Conclusion: Serum IL-6 might be considered as a predictor for metastatic prostate cancer. Along with PSA, serum IL-6 levels
could be a strong predictor for the diagnosis of metastatic condition of prostate cancer.


IL-6 levels, prostate specific antigen, metastatic and non- metastatic prostate cancer.

Full Text:



  • There are currently no refbacks.